Physician profile
Benjamin Robert Rahoy
NPI 1659891281
$5,348.56
in general payments reported to CMS, 2019-2025
37 companies · $1,019 in 2025
The $1,019 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.54 · 2021: $153 · 2022: $662 · 2023: $1,965 · 2024: $1,453 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,340 · Education: $75.45 · Consulting Fee: $21.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,340.02 |
| Education | $75.45 |
| Consulting Fee | $21.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $802.51 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $588.31 | 2022-2025 | |
| Amgen INC. | $536.15 | 2023-2024 | Tezspire, Evenity, Prolia |
| Regeneron Healthcare Solutions, INC. | $413.08 | 2023-2025 | Dupixent |
| Csl Behring | $333.41 | 2019-2025 | Hizentra, Kcentra |
| Grifols USA, LLC | $324.94 | 2022-2025 | Xembify |
| Glaxosmithkline, LLC. | $219.99 | 2022-2024 | Nucala, Arexvy, Shingrix |
| Pfizer INC. | $209.81 | 2023-2025 | |
| Genentech USA, INC. | $185.03 | 2022-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $174.96 | 2022-2025 | Takhzyro, Cuvitru |
| Abbvie INC. | $143.45 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.08 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $121.21 | 2024-2025 | Tremfya |
| Merck Sharp & Dohme LLC | $107.90 | 2022-2024 | Dificid |
| Lilly USA, LLC | $106.52 | 2022-2025 | Ebglyss, Taltz, Trulicity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rahoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.